MEHP, AhR, and Ovarian Follicle Toxicity
2026-08-14
This 2024 study identifies the aryl hydrocarbon receptor as a functional mediator of mono(2-ethylhexyl) phthalate toxicity in mouse ovarian antral follicles. Pharmacological AhR blockade partially restored follicle growth, estrogen production, and estrogen-responsive gene expression, providing a mechanistic framework for studying phthalate-associated reproductive toxicity.
Diethylmaleate for Redox Stress Workflows
2026-08-13
Diethylmaleate offers a practical way to deplete intracellular glutathione and test how redox buffering influences ROS, apoptosis, GST activity, and chemical resistance. This workflow-focused guide translates insecticide-resistance findings into controlled cell, toxicology, and organismal assay designs.
Trifluoperazine 2HCl: From Target to Translation
2026-08-13
A translational framework for using Trifluoperazine 2HCl to connect dopamine D2 receptor pharmacology with immune and oncology research, while applying the mechanism-to-phenotype rigor demonstrated in a landmark PDK4 inhibitor study.
CARMIL Membrane Binding Links CP to Actin Assembly
2026-08-12
Mooren and colleagues define a dual role for the CARMIL membrane-binding domain: it first recruits CARMIL-associated capping protein to a membrane and then can disengage after capping protein binding. This membrane-dependent transition provides a mechanistic explanation for how capping protein is activated, released from the membrane, and positioned to regulate Arp2/3-mediated actin assembly.
miR-519d-3p Exosomes in Preeclampsia
2026-08-12
The 2025 reference study links placenta-derived exosomal miR-519d-3p with immune intolerance in preeclampsia by showing effects on Jurkat T-cell proliferation, apoptosis, and Th17 differentiation. Its combined sequencing, molecular, and functional-cell approach provides a useful framework for investigating trophoblast–immune communication, while the in vitro model requires validation in primary cells and pregnancy models.
Clarithromycin: A CYP3A Probe for Better Assays
2026-08-11
Clarithromycin is a potent CYP3A inhibitor for drug-drug interaction research, but its greatest value comes from disciplined assay interpretation. This guide presents a pathway-centered design strategy using pharmacokinetic controls, solubility-aware handling, and the dabigatran literature as a mechanistic contrast.
Vitamin D/VDR and Endometrial Decidualization
2026-08-10
This study identifies a vitamin D/VDR signaling axis that promotes human endometrial stromal cell decidualization through CYP19 and ESR1 regulation. Its combined use of loss-of-function, gain-of-function, primary-cell validation, and ChIP-qPCR provides a mechanistic framework for studying vitamin D in endometrial receptivity and infertility research.
Cefepime (BMY-28142) for Infection Research
2026-08-09
Cefepime (BMY-28142) supports reproducible bacterial infection models, central nervous system infection research, and resistance-mechanism assays. This practical guide covers stock handling, microdilution design, barrier-model considerations, neurotoxicity controls, and lessons that can be adapted from large-scale cefiderocol surveillance.
KPT-330 (Selinexor): CRM1 Inhibition Guide
2026-08-08
KPT-330, also called Selinexor, is an orally bioavailable selective CRM1/XPO1 inhibitor used in cancer research. Evidence links CRM1 inhibition with nuclear retention of regulatory proteins, apoptosis and cell-cycle effects in cancer models, while a 2026 study extends preclinical investigation to osteoclastogenesis in osteoarthritis.
SGI-1027–Everolimus in Renal Cancer
2026-08-07
This study identifies SGI-1027 as a methuosis inducer in renal cancer and shows that it cooperates with everolimus to suppress tumor-cell growth, migration, and invasion. The proposed mechanism links lysosomal membrane permeability with apoptosis and GSDME-dependent pyroptosis, providing a framework for investigating lysosome-centered strategies against everolimus-resistant renal cell carcinoma.
SB-505124 Hydrochloride: Precision Inhibition in Fibrosis Mo
2026-08-07
SB-505124 hydrochloride enables high-fidelity dissection of TGF-β/activin signaling in fibrosis and mechanobiology research, with robust selectivity and non-cytotoxic delivery. Its validated performance in complex models, like glaucoma filtration surgery and advanced cancer mechanotransduction assays, sets a new standard for reproducibility and insight.
Ceramide-Driven Lipid Remodeling in Fish Nodavirus Infection
2026-08-06
This study employs lipidomics to unravel the pivotal pro-viral role of ceramides during red-spotted grouper nervous necrosis virus (RGNNV) infection. The findings highlight ceramide accumulation and autophagy as central mechanisms facilitating viral replication, offering new perspectives for experimental strategies in aquatic virology and cellular lipid research.
Fucoidan: Protocol Innovations in Breast Cancer Research
2026-08-06
Fucoidan, a sulfated α-L-fucan from brown seaweed, delivers selective cytotoxicity and novel mechanistic targeting in breast cancer models. This article translates the latest reference study and validated preclinical workflows into actionable protocols and troubleshooting strategies for oncology researchers.
METTL14–DHRS4-AS1/miR-206/A3AR Axis Modulates UC Inflammatio
2026-08-05
A recent study elucidates how METTL14-mediated m6A methylation regulates inflammation in ulcerative colitis by modulating the lncRNA DHRS4-AS1/miR-206/A3AR axis. These insights clarify epigenetic mechanisms in UC pathogenesis and suggest new therapeutic targets for inflammatory bowel disease.
Gemcitabine: DNA Synthesis Inhibitor for Cancer Research
2026-08-05
Gemcitabine is a potent DNA synthesis inhibitor, widely used in cancer research for its anti-tumor and pro-apoptotic effects. It disrupts DNA replication, activates checkpoint pathways, and has measurable efficacy in both in vitro and in vivo models. This review details its mechanisms, benchmarked applications, and protocol integration.
466 records 9/32 page Previous Next First page 上5页 678910 下5页 Last page